跳至主要内容
临床试验/jRCTs041240136
jRCTs041240136招募中不适用

The efficacy and safety of teriparatide among patients with chronic kidney disease stage 4 and 5

未提供0 个研究点目标入组 35 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
35
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Single Arm Study
干预模型
Single Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • Patients with chronic kidney disease stage 4 and 5 and meeting one of the following criteria
  • Meeting criteria for the diagnosis of osteoporosis
  • Trabecular bone score less than -2.0 and T score of bone mineral density more than -2.5 and less than -1.0

排除标准

  • Those on maintenance dialysis or expecting the initiation of dialysis within 2 years
  • Those who had kidney transplantation
  • Those on corticosteroid treatment, i.e. prednisolone equivalent dose more than 5mg a day
  • Intact PTH 150 pg/mL and over
  • Bone Paget disease
  • Alkaline phosphatase twice the upper limit of reference range or over
  • Previous radiation therapy to bones
  • Hypercalcemia
  • Primary bone malignancy or metastatic bone malignancy
  • Allergy to teriparatide
  • Pregnant women
  • Previous therapy with teriparatide

结局指标

主要结局

-

Increase in trabecular bone score in lumbar spine bone mineral density after 2 years

次要结局

  • Bone mineral densities
  • Trabecular volumetric bone mineral densities
  • Cortical volumetric bone mineral densities

研究者

发起方
未提供

相似试验